Briggs W. Morrison, M.D. has served as our Chief Executive Officer since June 2015 and as a member of our board of directors since July 2015. Dr. Morrison currently serves as a managing director of MPM Capital, a healthcare-focused venture capital firm, since June 2015. Prior to joining us, he served as Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca plc, a publicly traded company, from January 2012 to June 2015, leading the company’s global, late-stage development organization and serving as a member of the AstraZeneca senior executive team. He previously held a number of positions at Pfizer Inc., a publicly traded company, from 2007 to January 2012 that culminated in his appointment as Head, Medical Affairs, Safety and Regulatory Affairs for Pfizer’s human health business, and also served in roles of increasing responsibility at Merck Research Laboratories, a division of Merck & Co., Inc., from 1995 to 2007, ascending to the role of Vice President, Clinical Sciences, Oncology, responsible for clinical development of all novel anti-cancer drugs. Dr. Morrison currently serves on the board of Arvinas, Repare Therapeutics and Werewolf Therapeutics, each of which is a publicly traded company, as well as the boards of several private companies. Previously, he served on the board of Codiak Biosciences, Oncorus and NextCure Therapeutics. Dr. Morrison received a B.S. in biology from Georgetown University and an M.D. from the University of Connecticut.
What is Briggs Morrison's net worth?
The estimated net worth of Briggs Morrison is at least $284,484.20 as of August 9th, 2023. Dr. Morrison owns 17,836 shares of Syndax Pharmaceuticals stock worth more than $284,484 as of November 21st. This net worth estimate does not reflect any other investments that Dr. Morrison may own. Learn More about Briggs Morrison's net worth.
How do I contact Briggs Morrison?
Has Briggs Morrison been buying or selling shares of Syndax Pharmaceuticals?
Briggs Morrison has not been actively trading shares of Syndax Pharmaceuticals within the last three months. Most recently, Briggs Morrison sold 52,855 shares of the business's stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $18.27, for a transaction totalling $965,660.85. Following the completion of the sale, the director now directly owns 17,836 shares of the company's stock, valued at $325,863.72. Learn More on Briggs Morrison's trading history.
Who are Syndax Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Syndax Pharmaceuticals?
In the last year, Syndax Pharmaceuticals insiders bought shares 1 times. They purchased a total of 1,250 shares worth more than $25,037.50. The most recent insider tranaction occured on June, 14th when CFO Keith A Goldan bought 1,250 shares worth more than $25,037.50. Insiders at Syndax Pharmaceuticals own 4.1% of the company.
Learn More about insider trades at Syndax Pharmaceuticals. Information on this page was last updated on 6/14/2024.
